Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models

Toxicology

Volumn 221, Issue 2-3, 2006, Pages 241-248

  Hack, C Eric ^a  

^a Toxicology Excellence for Risk Assessment   (United States)

Author keywords

Bayesian; MCMC; PBPK; PBTK

Indexed keywords

ARTICLE; BAYES THEOREM; HEALTH HAZARD; MAXIMUM LIKELIHOOD METHOD; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; TOXICOKINETICS;

ANIMALS; BAYES THEOREM; HUMANS; MARKOV CHAINS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PHARMACOKINETICS; PHARMACOLOGY; PHYSIOLOGY; TOXICOLOGY;

ANIMALIA;

EID: 33645322633     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2005.12.017     Document Type: Article

References (16)

1. Allen et al. Use of Markov chain Monte Carlo analysis with a physiologically based pharmacokinetic model of methylmercury to estimate exposures in United States women of child-bearing age. Risk Anal., submitted for publication.
2. P. Bernillon, and F. Bois Statistical issues in toxicokinetic modeling: a Bayesian perspective Environ. Health Perspect. 108 Suppl. 5 2000 883 893
3. F. Bois, and D. Maszle MCSIM: a simulation program J. Stat. Software 2 9 1997 http://toxi.ineris.fr/activites/toxicologie_quantitative/mcsim/article3
4. F.Y. Bois Analysis of PBPK models for risk characterization Ann. N. Y. Acad. Sci. 895 1999 317 337
5. F. Bois Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics Environ. Health Perspect. 108 2 2000 307 316
6. H.J. Clewell, M.E. Andersen, and H.A. Barton A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment Environ. Health Perspect. 110 1 2002 85 93
7. David, R.M., Clewell, H.J., Gentry, P.R., Covington, T., Morgott, D.A., Marino, D.J., 1996. Revised assessment of cancer risk to dichloromethane using improved human metabolic parameters and Bayesian statistics, Reg. Tox. Pharm., in press.
8. EPA, 2001. Toxicological Review of Bromate. U.S. Environmental Protection Agency, Washington, DC.
9. A. Gelman, and D.B. Rubin Inference from iterative simulation using multiple sequences Stat. Sci. 7 1992 457 511
10. A. Gelman Inference and monitoring convergence W.R. Gilks S. Richardson D.J. Spiegelhalter Markov Chain Monte Carlo in Practice 1996 Chapman & Hall/CRC Boca Raton 131 143
11. A. Gelman, F. Bois, and J. Jiang Physiological pharmacokinetic analysis using population modeling and informative prior distributions J. Am. Stat. Assoc. 91 1996 1400 1412
12. W.R. Gilks, S. Richardson, and D.J. Spiegelhalter Introducing Markov chain Monte Carlo W.R. Gilks S. Richardson D.J. Spiegelhalter Markov Chain Monte Carlo in Practice 1996 Chapman & Hall/CRC Boca Raton 1 19
13. R.V. Hogg, and E.A. Tanis Probability and Statistical Inference fourth ed. 1993 Macmillan Publishing Company New York pp. 586-587
14. F. Jonsson, and G. Johanson A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane Toxicol. Appl. Pharmacol. 174 2001 99 112
15. Marino, D.J., Clewell 3rd, H.J., Gentry, P.R., Covington, T.R., Hack, C.E., David, R.M., Morgott, D.A., 1996. Bayesian PBPK and dose-response modeling of dichloromethane in mice. Reg. Tox. Pharm., in press.
16. USAF-EPA TCE PBPK Workgroup, 2004. Markov Chain Monte Carlo Analysis of Harmonized Physiologically-based Pharmacokinetic Model of Trichloroethylene and Its Metabolites, www.tera.org.